Prudential Financial’s Zevra Therapeutics ZVRA Stock Holding History

Prudential Financial’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$502K	Buy	+35,020	New	+$389K	﹤0.01%	1913

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Prudential Financial's ZVRA Position: Q2 2026 in Review

Prudential Financial opened a new position in Zevra Therapeutics (ZVRA) in Q2 2026: 35,020 shares worth $502K. The stake represents ﹤0.01% of the portfolio and ranks #1913 among its holdings.

157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

Prudential Financial held 35,020 shares of Zevra Therapeutics worth $502K as of Q2 2026.
Zevra Therapeutics was a new Prudential Financial position in Q2 2026.
Zevra Therapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q2 2026, its #1913 holding.
157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.